Previous 10 | Next 10 |
2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...
2024-01-08 08:01:09 ET Summary Merck is a pharmaceutical giant whose medications and vaccines play key roles in the fight against viruses, cancer, and cardiovascular diseases. On October 26, 2023, Merck published results for the 3rd quarter of 2023, which left mixed feelings. ...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
2024-01-06 10:15:00 ET Many people make it a New Year's resolution to save more money, and to that end, investing in stocks isn't a bad idea. Putting your hard-earned cash in solid corporations with bright futures will help grow your initial capital. And while the healthcare industry may no...
2024-01-05 14:31:55 ET More on AstraZeneca, Eli Lilly, etc. Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgra...
2024-01-05 11:31:43 ET More on Novo Nordisk Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity Novo Nordisk: Plenty More Room To Run Despite Its Hefty Valuation Novo Nordisk si...
2024-01-05 09:07:57 ET More on Big Pharma Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Bri...
2024-01-05 04:46:05 ET Merck ( NYSE: MRK ) is looking to tap into the booming obesity drug market as it seeks new therapies with benefits beyond weight loss. Speaking at an investor conference hosted by Goldman Sachs, Merck chief executive officer Rob Davis said that the company...
2024-01-04 17:29:02 ET Eli Lilly & Co (NYSE: LLY) was the talk of the market on Thursday after the pharmaceutical giant launched LillyDirect – a website that will enable patients to get prescription for its weight-loss drug directly from a telehealth provider. Cramer reco...
2024-01-04 14:24:43 ET Shares of WW International (NASDAQ: WW) , formerly Weight Watchers International, tumbled 11.4% through 1:10 p.m. ET on Thursday at the same time as Eli Lilly (NYSE: LLY) stock resumed its relentless march back toward its 52 week high. These two ev...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 07:07:00 ET If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the...
2024-07-30 05:48:00 ET Going into 2024, DexCom 's (NASDAQ: DXCM) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes. However, last week was the worst for De...
2024-07-29 15:13:21 ET Eli Lilly & Co (NYSE: LLY) has recently experienced a dramatic $123 billion decline in market value. This significant drop follows positive developments from competitors, notably Viking Therapeutics Inc and Roche Holding AG, who made announcements regarding th...